Monitor for U.S. site activation announcements and any early enrollment updates. The key catalyst will be topline data in Q4 2027; no near-term binary events.
Price Chart
Executive Summary
Edesa Biotech announced FDA clearance of its IND application for EB06, a monoclonal antibody targeting CXCL10, enabling a Phase 2 vitiligo study to expand recruitment into the U.S. Patient enrollment is already underway in Canada, with first U.S. sites expected next quarter and topline data anticipated in Q4 2027. This is a clinical milestone that de-risks the program's regulatory path but remains early-stage with no revenue or efficacy data.
Key Facts
- FDA cleared IND for Phase 2 study of EB06 in vitiligo
- Study is double-blind, placebo-controlled, enrolling up to 80 adults with moderate-to-severe nonsegmental vitiligo
- Participants randomized 1:1 to EB06 or placebo every two weeks through Week 22
- Primary endpoint: mean percent change from baseline in F-VASI at Week 28
- Topline data expected Q4 2027
- First U.S. sites expected to begin enrolling next quarter
Financial Impact
No financial figures reported in the filing
Risk Factors
- Clinical trial risk: EB06 may fail to meet primary endpoint
- Regulatory risk: safety or tolerability issues could delay or halt the program
- Competitive risk: other vitiligo therapies (e.g., JAK inhibitors) may advance faster
- Financing risk: the company may need to raise capital to complete the study
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-006647 |
| Document: 0001171843-26-006647-index-headers.html | 0001171843-26-006647 |
| Document: 0001171843-26-006647-index.html | 0001171843-26-006647 |
| Document: 0001171843-26-006647.txt | 0001171843-26-006647 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $2.59 | awaiting T+20 | — | $2.63 (+1.54%) |
Oct 15, 2026 12d ago | 8-K | $2.67 | awaiting T+20 | — | $2.63 (−1.50%) |
Oct 15, 2026 12d ago | Press Release | $2.67 | awaiting T+20 | — | $2.63 (−1.50%) |
Aug 19, 2026 9w ago | Press Release | $4.76 $4.14 | ▲ +13.03% | ▲ +13.03% | $2.63 (+44.75%) |
Jul 14, 2026 15w ago | EFFECT | $6.74 $5.52 | ▲ +18.10% | ▲ +20.59% | $2.63 (+60.98%) |
Jul 2, 2026 16w ago | S-3 | $7.50 $5.25 | ▼ −30.00% | ▼ −29.59% | $2.63 (−64.93%) |
Jun 5, 2026 20w ago | 8-K | $5.46 $7.21 | ▲ +32.05% | ▲ +30.19% | $2.63 (−51.83%) |
Jun 5, 2026 20w ago | Press Release | $5.46 $7.21 | ▲ +32.05% | ▲ +30.19% | $2.63 (−51.83%) |
May 29, 2026 21w ago | 8-K | $6.69 $8.13 | ▲ +21.52% | ▲ +22.82% | $2.63 (−60.69%) |
May 19, 2026 23w ago | Press Release | $11.95 $6.88 | ▼ −42.43% | ▼ −43.41% | $2.63 (−77.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers